ストックスクリーナーアプリを入手
0.1876
21.52%
-0.0225
アフターアワーズ：
.19
0.00245
+1.31%
前日終値:
$0.21
開ける：
$0.22
24時間の取引高:
25,321
Relative Volume:
66.00
時価総額：
$N/A
収益：
-
当期純損益:
$-16.08M
株価収益率:
-0.00545
EPS:
-34.43
ネットキャッシュフロー:
$-11.54M
1週間 パフォーマンス:
-21.52%
1か月 パフォーマンス:
-80.61%
6か月 パフォーマンス:
-86.27%
1年 パフォーマンス:
-97.18%
1日の値動き範囲:
$0.1876
$0.2285
1週間の範囲:
$0.1876
$0.2285
52週間の値動き範囲:
$0.1876
$0.2285
Bio Path Holdings Inc Stock (BPTH) Company Profile
BPTH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.1876 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-11 | 開始されました | ROTH Capital | Buy |
| 2017-11-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-04-18 | 開始されました | Rodman & Renshaw | Buy |
| 2014-06-02 | 再開されました | Maxim Group | Buy |
| 2014-05-09 | 開始されました | Maxim Group | Buy |
すべてを表示
Bio Path Holdings Inc (BPTH) 最新ニュース
Life Sciences Investor Forum: Now Available for Online Viewing - The Manila Times
GitLab (NASDAQ:GTLB) Price Target Cut to $52.00 by Analysts at JPMorgan Chase & Co. - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 870.6% in May - Defense World
Life Sciences Investor Forum Agenda Announced for June 11th-12th - GlobeNewswire
Bio-Path Holdings to Present at Life Sciences Virtual Investor F - GuruFocus
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum | BPTH Stock News - GuruFocus
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum - The Manila Times
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia - The Manila Times
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - The Manila Times
Roth Capital Issues Negative Estimate for Bio-Path Earnings - Defense World
Roth Capital Forecasts Bio-Path FY2029 Earnings - Defense World
“Intel Foundry Will Need to Earn (Intel’s) Business”: Intel Stock (NASDAQ:INTC) Slips as Intel Looks for Better Deal Than Intel - The Globe and Mail
When is Comtech's Q3 Earnings? Key Date and Conference Call Details Revealed - Stock Titan
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 | BPTH Stock News - GuruFocus
Oil-Dri Delivers Massive 16% Dividend Hike After 22 Years of Unbroken Growth - Stock Titan
Bio-Path's Breakthrough: Phase 2 Leukemia Drug Advances While New Cancer Treatments Show Promise - Stock Titan
Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 - Stock Titan
ChargePoint Q1 Earnings Show 31% Margins, Eaton Partnership Powers New Growth Strategy - Stock Titan
Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns - Insider Monkey
Q.ANT Debuts First Interactive Live Demonstration and New Benchmarks for Analog Photonic Computing at ISC 2025 - Newsfile
Bio-Path's (BPTH) Price Target Reduced by Roth Capital Amid Pipe - GuruFocus
Bio-Path's (BPTH) Price Target Reduced by Roth Capital Amid Pipeline Updates | BPTH Stock News - GuruFocus
BPTH: Bio-Path's Latest Clinical Developments and Milestones | B - GuruFocus
Robinhood Markets Hits 52-Week High: Should You Buy the Stock Now? - The Globe and Mail
Bio-Path Holdings Provides Clinical and Operational Update | BPT - GuruFocus
BPTH: Bio-Path's Latest Clinical Developments and Milestones | BPTH Stock News - GuruFocus
Bio-Path Holdings Provides Clinical and Operational Update - The Manila Times
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - The Manila Times
Bio-Path Holdings Provides Clinical and Operational Update | BPTH Stock News - GuruFocus
Bio-Path Holdings, Inc. Provides Update on Clinical Development Progress and Pipeline Advances - Nasdaq
Bio-Path Clinical Trial Breakthrough: Cancer Patients Achieve Complete Remission After 15+ Treatment Cycles - Stock Titan
Auric Minerals Corp. Announces Closing of Property Transaction - The Globe and Mail
Blokees made its debut at CCXP México 2025, Officially Enters México Market - The Globe and Mail
Colgate-Palmolive Reshapes Executive Team: Danone Deputy CEO Joins as Americas COO in Strategic Growth Push - Stock Titan
Cytokinetics Management Reveals Latest Updates at Jefferies Healthcare ConferenceLive Webcast Available - Stock Titan
Transcript : Bio-Path Holdings, Inc.Special Call - marketscreener.com
Toyota Signs Rising Latin Star Ela Taubert as Tour Sponsor: Major US Concert Series Coming - Stock Titan
Revolutionary AI Nose Technology Hits 85% Accuracy, Targets $76.5B SmellTech Market for Eldercare Crisis - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
Lantronix Launches Revolutionary AI Network Manager for $400M Console Server Market at Cisco Live - Stock Titan
Gentherm Leadership Team Announces Packed Schedule: 3 Key Investor Conferences Coming in June 2025 - Stock Titan
TITAN INTERNATIONAL, INC. TO PARTICIPATE IN JUNE CONFERENCES - Stock Titan
GunBroker.com Founder Takes $1 Salary as New CEO: Inside the Major Leadership Shakeup at Outdoor Holding - Stock Titan
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress - Stock Titan
Chevron Stockholders Show Overwhelming Support: Key Takeaways from 2025 Annual Meeting Results - Stock Titan
Air Products CEO Set to Share Industry Outlook at Major Deutsche Bank Industrial Conference - Stock Titan
Rigel to Present at the Jefferies Global Healthcare Conference - Stock Titan
Solid Biosciences Leadership Team to Reveal Latest Genetic Medicine Strategy at Major Healthcare Conference - Stock Titan
BlackBerry QNX Launches Game-Changing Software Platform as 90% of Future Vehicles Need Advanced Computing - Stock Titan
REX American Resources Launches Massive $32.7M Share Buyback Program Amid Strong Q1 Earnings - Stock Titan
Elanco Taps Hillenbrand CFO to Drive Next Growth Phase After 7 Straight Growth Quarters - Stock Titan
Bio Path Holdings Inc (BPTH) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):